-
EP3197450
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3197450
| EP3197450 - MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF FIBROSIS [Right-click to bookmark this link] | |||
| Former [2017/31] | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | ||
| [2021/23] | Status | Examination is in progress Status updated on 09.12.2019 Database last updated on 03.06.2024 | |
| Former | Request for examination was made Status updated on 30.06.2017 | ||
| Former | The international publication has been made Status updated on 21.03.2017 | Most recent event Tooltip | 15.04.2024 | New entry: Despatch of communication that application is refused | Applicant(s) | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris Cédex 13 / FR | For all designated states Université Paris Cité 85 boulevard Saint-Germain 75006 Paris / FR | For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75016 Paris / FR | [2022/19] |
| Former [2021/40] | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris Cédex 13 / FR | ||
| For all designated states Université de Paris 85 boulevard Saint-Germain 75006 Paris / FR | |||
| For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75016 Paris / FR | |||
| Former [2017/31] | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris Cédex 13 / FR | ||
| For all designated states Université Paris Diderot - Paris 7 5, rue Thomas Mann 75013 Paris / FR | |||
| For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75016 Paris / FR | Inventor(s) | 01 /
LOTERSZTAJN, Sophie Centre De Recherche Sur L'inflammation INSERM-UMR1149 Université Paris-Diderot Faculte De Medecine-site Xavier Bichat, 16 Rue Henri Huchard, Bp 416 - 4eme Etage F-75018 Paris / FR | 02 /
HABIB, Aïda Centre De Recherche Sur L'inflammation INSERM-UMR1149 Université Paris-Diderot Faculte De Medecine-site Xavier Bichat, 16 Rue Henri Huchard, Bp 416 - 4eme Etage F-75018 Paris / FR | [2017/31] | Representative(s) | Inserm Transfert PariSanté Campus 10 rue d'Oradour-sur-Glane 75015 Paris / FR | [N/P] |
| Former [2017/31] | Collin, Matthieu Inserm-Transfert Paris Biopark 7, rue Watt 75013 Paris / FR | Application number, filing date | 15766500.1 | 21.09.2015 | [2017/31] | WO2015EP71597 | Priority number, date | EP20140306456 | 22.09.2014 Original published format: EP 14306456 | [2017/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016046130 | Date: | 31.03.2016 | Language: | EN | [2016/13] | Type: | A1 Application with search report | No.: | EP3197450 | Date: | 02.08.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.03.2016 takes the place of the publication of the European patent application. | [2017/31] | Search report(s) | International search report - published on: | EP | 31.03.2016 | Classification | IPC: | A61K31/435, A61K45/00, A61K31/496, A61P11/00 | [2017/31] | CPC: |
A61K31/496 (EP,US);
A61K31/4015 (EP,US);
A61K31/4525 (EP,US);
A61K31/4535 (EP,US);
A61K31/454 (EP,US);
A61K31/4545 (EP,US);
A61P1/16 (EP);
A61P1/18 (EP);
A61P11/00 (EP);
A61P13/12 (EP);
A61P17/02 (EP);
A61P19/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/31] | Title | German: | MONOACYLGLYCEROL LIPASE INHIBITOREN ZUR BEHANDLUNG VON FIBROSE | [2021/23] | English: | MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF FIBROSIS | [2021/23] | French: | INHIBITEURS DE MONOACYLGLYCÉROL LIPASE POUR LE TRAITEMENT DE LA FIBROSE | [2021/23] |
| Former [2017/31] | VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON FIBROSE | ||
| Former [2017/31] | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | ||
| Former [2017/31] | PROCÉDÉS ET COMPOSITIONS PHARMACEUTIQUES DESTINÉS AU TRAITEMENT DE LA FIBROSE | Entry into regional phase | 21.03.2017 | National basic fee paid | 21.03.2017 | Designation fee(s) paid | 21.03.2017 | Examination fee paid | Examination procedure | 21.03.2017 | Amendment by applicant (claims and/or description) | 21.03.2017 | Examination requested [2017/31] | 21.03.2017 | Date on which the examining division has become responsible | 12.12.2019 | Despatch of a communication from the examining division (Time limit: M04) | 10.04.2020 | Reply to a communication from the examining division | 04.11.2020 | Despatch of a communication from the examining division (Time limit: M02) | 15.12.2020 | Reply to a communication from the examining division | 20.07.2021 | Despatch of a communication from the examining division (Time limit: M02) | 20.09.2021 | Reply to a communication from the examining division | 29.01.2024 | Cancellation of oral proceeding that was planned for 03.05.2024 | 16.04.2024 | Despatch of communication that the application is refused, reason: substantive examination {1} | 03.05.2024 | Date of oral proceedings (cancelled) | Fees paid | Renewal fee | 22.09.2017 | Renewal fee patent year 03 | 21.09.2018 | Renewal fee patent year 04 | 19.09.2019 | Renewal fee patent year 05 | 17.09.2020 | Renewal fee patent year 06 | 21.09.2021 | Renewal fee patent year 07 | 21.09.2022 | Renewal fee patent year 08 | 20.09.2023 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2004056800 (JANSSEN PHARMACEUTICA NV [BE], et al) [X] 1-3,5 * page 21, paragraph 2 * [I] 4; | [XD]WO2010124082 (JANSSEN PHARMACEUTICA NV [BE], et al) [XD] 1,5 * claim 18 *; | [X]US2012058986 (CONNOLLY PETER J [US], et al) [X] 1,5 * claim 15 *; | [XI]WO2013049332 (INFINITY PHARMACEUTICALS INC [US]) [X] 1,5 * fibrosing; page 76, line 5 * * rheumatoid arthritis; page 76, lines 13,14 * * glomerulonephritis; page 76, line 20 * * eosinophilic gastrointestinal disorders; page 76, lines 24,25 * * scarring; page 77, line 5 * * morphea, nephrotic syndrome, polymyositis; page 76, lines 29,30 *[I] 2-4; | [XD]US8513423 (CONNOLLY PETER J [US], et al) [XD] 1,5 * column 6, line 65 * |